Coherus Oncology, Inc. (CHRS) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 75.51M USD | Liabilities, Current |
| Cash and equivalents | 82.92M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 22.38M USD | Marketable Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 5.67M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $75.51M | $82.92M | $22.38M | (m) | $5.67M | (m) |
| 2026-03-31 | (m) | $132.33M | $115.24M | $51.81M | (m) | $4.83M | (m) |
| 2025-12-31 | (m) | $140.39M | $88.88M | $83.25M | (m) | $3.17M | (m) |
| 2025-09-30 | (m) | $372.30M | $103.35M | $88.31M | (m) | $2.05M | (m) |
| 2025-06-30 | (m) | $263.63M | $216.89M | $20.74M | (m) | $4.51M | (m) |
| 2025-03-31 | (m) | $255.04M | $82.41M | (m) | (m) | $3.52M | (m) |
| 2024-12-31 | (m) | $282.98M | $125.99M | (m) | (m) | $70.09M | (m) |
| 2024-09-30 | (m) | $295.57M | $97.69M | (m) | (m) | $47.64M | (m) |
| 2024-06-30 | (m) | $463.00M | $159.24M | (m) | (m) | $62.16M | (m) |
| 2024-03-31 | (m) | $538.30M | $259.77M | (m) | (m) | $61.98M | (m) |
| 2023-12-31 | (m) | $331.77M | $102.89M | $14.86M | (m) | $62.60M | (m) |
| 2023-09-30 | (m) | $239.66M | $80.26M | $50.82M | (m) | $66.78M | (m) |
| 2023-06-30 | (m) | $169.44M | $72.92M | $71.79M | (m) | $63.99M | (m) |
| 2023-03-31 | (m) | $123.41M | $16.14M | $111.94M | (m) | $49.41M | (m) |
| 2022-12-31 | (m) | $138.69M | $63.55M | $128.13M | (m) | $38.79M | (m) |
| 2022-09-30 | (m) | $171.32M | $286.81M | (m) | (m) | $27.72M | (m) |
| 2022-06-30 | (m) | $140.75M | $275.48M | (m) | (m) | $31.74M | (m) |
| 2022-03-31 | (m) | $153.75M | $325.68M | (m) | (m) | $36.95M | (m) |
| 2021-12-31 | (m) | $165.33M | $417.19M | (m) | (m) | $37.64M | (m) |
| 2021-09-30 | (m) | $320.35M | $360.54M | $108.17M | (m) | $37.58M | (m) |
| 2021-06-30 | (m) | $287.05M | $329.74M | $124.68M | (m) | $39.67M | (m) |
| 2021-03-31 | (m) | $257.60M | $259.49M | $140.01M | (m) | $51.61M | (m) |
| 2020-12-31 | (m) | $145.65M | $541.16M | (m) | (m) | $44.23M | (m) |
| 2020-09-30 | (m) | $133.43M | $292.46M | $210.97M | (m) | $35.25M | (m) |
| 2020-06-30 | (m) | $129.76M | $224.62M | $231.88M | (m) | $27.19M | (m) |
| 2020-03-31 | (m) | $119.01M | $193.25M | (m) | (m) | $16.44M | (m) |
| 2019-12-31 | (m) | $114.97M | $177.67M | (m) | (m) | $9.81M | (m) |
| 2019-09-30 | (m) | $82.70M | $165.12M | $5.38M | (m) | $7.67M | (m) |
| 2019-06-30 | (m) | $61.23M | $105.93M | $5.99M | (m) | $4.33M | (m) |
| 2019-03-31 | (m) | $41.41M | $81.52M | $14.92M | (m) | $2.31M | (m) |
| 2018-12-31 | (m) | $33.26M | $72.36M | (m) | (m) | $1.66M | (m) |
| 2018-09-30 | (m) | $24.54M | $101.20M | $15.97M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $22.20M | $130.00M | $29.81M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $27.62M | $82.02M | $13.14M | (m) | (m) | (m) |
| 2017-12-31 | (m) | $28.39M | $126.91M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $31.43M | $135.56M | $14.49M | (m) | (m) | (m) |
| 2017-06-30 | (m) | $35.95M | $73.35M | $44.98M | (m) | (m) | (m) |
| 2017-03-31 | $174.85M | $47.30M | $124.92M | $49.90M | $26.00K | (m) | 3.70× |
| 2016-12-31 | (m) | $56.38M | $124.95M | (m) | $1.86M | (m) | (m) |
| 2016-09-30 | (m) | $58.39M | $159.68M | (m) | $419.00K | (m) | (m) |
| 2016-06-30 | (m) | $108.28M | $220.92M | (m) | $419.00K | (m) | (m) |
| 2016-03-31 | (m) | $92.92M | $179.56M | (m) | $1.20M | (m) | (m) |
| 2015-12-31 | (m) | $106.02M | $158.23M | (m) | $1.56M | (m) | (m) |
| 2015-09-30 | (m) | $82.52M | $153.69M | (m) | $540.00K | (m) | (m) |
| 2015-06-30 | (m) | $69.95M | $206.09M | (m) | $1.45M | (m) | (m) |
| 2015-03-31 | (m) | $51.91M | $115.14M | (m) | $2.02M | (m) | (m) |
| 2014-12-31 | (m) | $51.78M | $150.39M | (m) | $2.42M | (m) | (m) |
| 2014-09-30 | (m) | $48.08M | $100.88M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $108.87M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $56.32M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $53.70M | $39.55M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | $34.72M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $14.55M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $7.68M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |